文献速递淋巴瘤造血干细胞移植与细胞治疗

在异基因干细胞移植预处理方案中加入奥英妥珠单抗的安全性与长期生存结果:一项单中心1、2期试验

Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
PubMed 文献 · Am J Hematol · 2024-02-23

这项单中心1、2期试验在复发CD22阳性淋巴系统恶性肿瘤拟行造血干细胞移植的患者中,将递增剂量奥英妥珠单抗(0.6、1.2或1.8 mg/m2,第13天)加入含烷化剂的预处理方案。26例患者入组,1期6例(23%)中4例接受0.6 mg/m2、2例接受1.2 mg/m2,均未出现剂量限制性毒性;2期20例(77%)接受最大剂量1.8 mg/m2。1例发生VOD,该患者移植前刚接受纳武利尤单抗且同时发生超急性GVHD。5年治疗相关死亡率为12%,中位随访48.7个月时5年总生存率和无进展生存率分别为84%和80%。

要点

  • 26例复发CD22阳性淋巴系统恶性肿瘤患者接受含奥英妥珠单抗预处理移植,1期6例未出现剂量限制性毒性。
  • 5年治疗相关死亡率为12%,中位随访48.7个月时5年总生存率84%、无进展生存率80%。
  • 1例发生VOD,该患者移植前刚接受纳武利尤单抗且同时发生超急性GVHD。

核心结论

  • 奥英妥珠单抗与含烷化剂的造血干细胞移植预处理方案联合时是安全的,未增加VOD风险。

研究设计与样本

  • 单中心1、2期前瞻性研究,纳入26例拟行造血干细胞移植的复发CD22阳性淋巴系统恶性肿瘤患者。
  • 1期6例(23%)接受递增剂量奥英妥珠单抗0.6 mg/m2(4例)或1.2 mg/m2(2例),第13天给药。
  • 2期20例(77%)接受最大剂量1.8 mg/m2,第13天给药。
  • 与接受相同预处理但未加奥英妥珠单抗的历史队列(n=56)进行比较。

主要发现

  • 1期6例患者均未出现剂量限制性毒性。
  • 1例发生VOD,该患者移植前刚接受纳武利尤单抗且同时发生超急性GVHD。
  • 5年治疗相关死亡率为12%。
  • 中位随访48.7个月时,5年总生存率为84%,无进展生存率为80%。
  • 与历史对照队列(n=56)相比,奥英妥珠单抗组在肝毒性发生率、植入时间、治疗相关死亡率或急性GVHD风险方面无显著差异。

临床怎么用

  • 原文结论认为奥英妥珠单抗与含烷化剂的造血干细胞移植预处理方案联合时是安全的,未增加VOD风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here we report on the first prospective study evaluating the safety and long-term survival when an escalating dose of inotuzumab ozogamicin (INO) (0.6, 1.2, or 1.8 mg/m2 on day 13) was added to one alkylator-containing conditioning regimen in patients with relapsed CD22 (+) lymphoid malignancies who were candidates for hematopoietic stem cell transplantation (HSCT). Twenty-six patients were enrolled. Six (23%) of these patients entered the phase 1 study: four were treated at an INO dose of 0.6 mg/m2 and two at dose of 1.2 mg/m2. None of these patients experienced dose-limiting toxicities. The remaining 20 (77%) patients entered the phase 2 part of the study at the maximum dose of 1.8 mg/m2. One patient developed VOD; this patient had received nivolumab immediately before HSCT while simultaneously experiencing hyperacute graft-vs-host disease (GVHD). Treatment-related mortality (TRM) at 5 years was 12%. With a median follow-up of 48.7 months, the 5-year overall survival (OS) and progression-free survival (PFS) rates were 84% and 80%, respectively. Compared with a historical cohort who received same conditioning for HSCT but without INO (n = 56), the INO group showed no significant differences in incidence of liver toxicity, engraftment time, TRM, or risk of acute GVHD. Patients with lymphoma who received INO had a trend for a better 5-year OS (93% versus 68%) and PFS (93% versus 58%) than those in the control group. In conclusion, our results showed that INO is safe with no increased risk of VOD when combined with one alkylator-containing regimen of HSCT.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Khouri IF, Alzahrani K, Kantarjian H, et al. Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial. Am J Hematol. 2024. PMID: 38400519. doi:10.1002/ajh.27254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。